Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study page now indicates recruitment is closed to new participants, and new help-related sections (How to Read a Study Record, Common Questions, How to Join a Study) were added, alongside a minor formatting change to the Intervention/Treatment label and removal of the prior revision note.SummaryDifference0.4%

- Check21 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5 on the page, indicating a minor behind-the-scenes update to the site's revision history.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page's revision label has been updated to v3.5.4, signaling a newer release of the site. This update does not alter the displayed study details or navigation.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page metadata shows an interface/release revision bump from v3.5.2 to v3.5.3, with no changes to the underlying ClinicalTrials.gov study content.SummaryDifference0.0%

- Check71 days agoChange Detected- Revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check78 days agoChange DetectedUpdate of the Italy location entry from Padua, Italy, 35128 to Padova, Italy, 35128.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.